These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22766031)

  • 1. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.
    Ray NJ; Miyasaki JM; Zurowski M; Ko JH; Cho SS; Pellecchia G; Antonelli F; Houle S; Lang AE; Strafella AP
    Neurobiol Dis; 2012 Dec; 48(3):519-25. PubMed ID: 22766031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nigrostriatal and Mesolimbic D
    Stark AJ; Smith CT; Lin YC; Petersen KJ; Trujillo P; van Wouwe NC; Kang H; Donahue MJ; Kessler RM; Zald DH; Claassen DO
    J Neurosci; 2018 Mar; 38(13):3230-3239. PubMed ID: 29483278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.
    Narendran R; Frankle WG; Mason NS; Rabiner EA; Gunn RN; Searle GE; Vora S; Litschge M; Kendro S; Cooper TB; Mathis CA; Laruelle M
    Synapse; 2009 Jun; 63(6):447-61. PubMed ID: 19217025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
    Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
    Neurology; 2000 Apr; 54(7):1482-7. PubMed ID: 10751262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease.
    Ko JH; Antonelli F; Monchi O; Ray N; Rusjan P; Houle S; Lang AE; Christopher L; Strafella AP
    Hum Brain Mapp; 2013 Jul; 34(7):1591-604. PubMed ID: 22331665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic function and intertemporal choice.
    Joutsa J; Voon V; Johansson J; Niemelä S; Bergman J; Kaasinen V
    Transl Psychiatry; 2015 Jan; 5(1):e491. PubMed ID: 25562841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.
    Steeves TD; Miyasaki J; Zurowski M; Lang AE; Pellecchia G; Van Eimeren T; Rusjan P; Houle S; Strafella AP
    Brain; 2009 May; 132(Pt 5):1376-85. PubMed ID: 19346328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride.
    Boileau I; Payer D; Chugani B; Lobo D; Behzadi A; Rusjan PM; Houle S; Wilson AA; Warsh J; Kish SJ; Zack M
    Addiction; 2013 May; 108(5):953-63. PubMed ID: 23167711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathological gambling and Parkinson disease].
    Fujimoto K
    Brain Nerve; 2008 Sep; 60(9):1039-46. PubMed ID: 18807938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.
    Aalto S; Hirvonen J; Kaasinen V; Hagelberg N; Kajander J; Någren K; Seppälä T; Rinne JO; Scheinin H; Hietala J
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):475-83. PubMed ID: 18985345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accentuated Paralimbic and Reduced Mesolimbic D
    Stark AJ; Song AK; Petersen KJ; Hay KR; Lin YC; Trujillo P; Kang H; Collazzo JM; Donahue MJ; Zald DH; Claassen DO
    J Neurosci; 2023 Dec; 43(50):8733-8743. PubMed ID: 37852792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No effect of dopamine depletion on the binding of the high-affinity D 2/3 radiotracer [11C]FLB 457 in the human cortex.
    Frankle WG; Mason NS; Rabiner EA; Ridler K; May MA; Asmonga D; Chen CM; Kendro S; Cooper TB; Mathis CA; Narendran R
    Synapse; 2010 Dec; 64(12):879-85. PubMed ID: 20506387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.
    Song AK; Hay KR; Trujillo P; Aumann M; Stark AJ; Yan Y; Kang H; Donahue MJ; Zald DH; Claassen DO
    Brain; 2022 Oct; 145(10):3488-3499. PubMed ID: 34951464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
    Gallagher DA; O'Sullivan SS; Evans AH; Lees AJ; Schrag A
    Mov Disord; 2007 Sep; 22(12):1757-63. PubMed ID: 17580327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.
    Narendran R; Mason NS; Chen CM; Himes M; Keating P; May MA; Rabiner EA; Laruelle M; Mathis CA; Frankle WG
    Synapse; 2011 Oct; 65(10):991-7. PubMed ID: 21360596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations.
    Balconi M; Angioletti L; Siri C; Meucci N; Pezzoli G
    Psychiatry Res; 2018 Dec; 270():974-980. PubMed ID: 29580652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity.
    Clark L; Stokes PR; Wu K; Michalczuk R; Benecke A; Watson BJ; Egerton A; Piccini P; Nutt DJ; Bowden-Jones H; Lingford-Hughes AR
    Neuroimage; 2012 Oct; 63(1):40-6. PubMed ID: 22776462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO.
    Boileau I; Payer D; Chugani B; Lobo DS; Houle S; Wilson AA; Warsh J; Kish SJ; Zack M
    Mol Psychiatry; 2014 Dec; 19(12):1305-13. PubMed ID: 24322203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.
    Antonelli F; Ko JH; Miyasaki J; Lang AE; Houle S; Valzania F; Ray NJ; Strafella AP
    Hum Brain Mapp; 2014 Jun; 35(6):2499-506. PubMed ID: 24038587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.